Courtesy Getty Images ABO incompatibility in HDFN can decrease the risk of sensitization to other red blood cell antibodies, including anti-D, anti-c or anti-Kell. Hemolytic disease of the fetus and ...

The Kpa antigen has an estimated prevalence of less than 2% in white populations, with an even lower prevalence in other ethnic groups. The Kp a antigen, which is one of 38 antigens in the Kell blood ...

Severe HDFN cases appear to be falling relative to historical estimates. HDFN is a disease that is provoked when the mother produces antibodies that attack the red blood cells of her fetus. The most ...

A recent study showed the Kell antigen, which is associated with HDFN, is rare in a particular population descending from Nigeria. “Kell blood group is associated with haemolytic transfusion reactions ...

Courtesy Getty Images Learn more about intrauterine transfusions, including their history and how they changed the treatment landscape of HDFN. Intrauterine transfusions (IUTs) are a cornerstone of ...

Newborn baby on white blanket in wicker crib, closeup HDFN caused by ABO incompatibility is usually less severe than HDFN caused by Rh incompatibility. What is HDFN? Hemolytic disease of the fetus and ...

Research shows a very low risk of developing antibodies tied to HDFN before 12 weeks, which could change routine care. Early evidence now shows that forgoing RhD immune globulin (RhIG) in most ...

Newborn baby is an in incubator and her eyes are covered with protective eye patches in a hospital in Oslo, Norway. The newborn baby is undergoing light therapy due to jaundice. She is put under a ...

The majority of cases of hemolytic disease of the fetus and newborn (HDFN) are due to RhD, Kell, or ABO antigen incompatibility. The case involved a newborn delivered at 37 weeks of gestation after an ...

Results of the study showed that based on the current prehospital transfusion rates in Finland, an estimated one to three patients with severe HDFN attributable to prehospital LTOWB transfusions every ...

An unusual case of hemolytic disease of the fetus and newborn (HDFN) caused by anti-LU1 (anti-Luᵃ) alloantibodies was recently published in Transfusion Medicine and Hemotherapy HDFN typically is a ...

This decision is based on clinical evidence from the phase 2 open-label UNITY clinical trial, in which pregnant women at high risk for HDFN were treated with nipocalimab. The U.S. Food and Drug ...